Not available
Quote | Agenus Inc. (NASDAQ:AGEN)
Last: | $10.70 |
---|---|
Change Percent: | 0.55% |
Open: | $10.8 |
Close: | $10.70 |
High: | $11.15 |
Low: | $10.5051 |
Volume: | 285,849 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
News | Agenus Inc. (NASDAQ:AGEN)
2024-05-16 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensili...
Message Board Posts | Agenus Inc. (NASDAQ:AGEN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $AGEN News Article - Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI | whytestocks | investorshangout | 05/03/2023 6:35:51 PM |
shalbyj: TheStreetReports: AI Biotech Stocks to Watch 2023: $IPA, $ONTX, $AGEN, $PBIO https://www.ma | shalbyj | investorshangout | 04/25/2023 1:37:15 PM |
whytestocks: $AGEN News Article - Agenus Receives Fast Track Designation for Botensilimab and Balsti | whytestocks | investorshangout | 04/17/2023 12:00:59 PM |
whytestocks: $AGEN News Article - Agenus' Botensilimab in Combination with Balstilimab Shows 33% Dur | whytestocks | investorshangout | 03/27/2023 3:10:50 PM |
whytestocks: $AGEN News Article - Best Penny Stocks To Buy Now: 3 To Watch Before Next Week | whytestocks | investorshangout | 03/15/2023 8:20:47 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-05-16 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensili...
2024-05-07 17:45:24 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2024 Earnings Call May 07, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2024 Earnings Call Transcript